Seagen (SGEN) Stock News, Jun-Oct 2023

SGEN Nasdaq

10/22/2023 10:30 AM

News

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.64%

Tags

-

10/16/2023 08:00 AM

News

Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.41%

Tags

-

10/12/2023 08:00 AM

News

Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.02%

Tags

09/22/2023 05:00 AM

News

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.54%

Tags

-

09/04/2023 03:00 PM

News

Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.35%

Tags

-

09/04/2023 03:00 PM

News

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.35%

Tags

08/16/2023 08:00 AM

News

Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.44%

Tags

-

08/02/2023 08:00 AM

News

Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.28%

Tags

-

07/12/2023 08:00 AM

News

Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.51%

Tags

06/20/2023 08:30 AM

News

Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.23%

Tags